For 130 years, Merck, known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases in pursuit of its mission to save and improve lives. It demonstrates its commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to prevent and treat diseases that threaten people and animals - including cancer, infectious diseases such as HIV and Ebola, and emerging animal diseases - as we aspire to be the premier research-intensive biopharmaceutical company in the world.
Company profile
Ticker
MRK
Exchange
Website
CEO
Kenneth Frazier
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Merck & Co. Inc., SCHERING PLOUGH CORP
SEC CIK
Corporate docs
Subsidiaries
7728026 Canada Inc. • Abmaxis Inc. • Acceleron Pharma Inc. • Afferent Pharmaceuticals, Inc. • Agrident GmbH • Agro Verhen B.V. • Aleis Pty Ltd • Allflex Argentina S.A. • Allflex Australia • Allflex dan-mark ApS ...
IRS number
221918501
MRK stock data
Analyst ratings and price targets
Latest filings (excl ownership)
8-K
Submission of Matters to a Vote of Security Holders
26 May 23
SD
Conflict minerals disclosure
22 May 23
PX14A6G
Letter to shareholders
18 May 23
8-K
Other Events
17 May 23
424B5
Prospectus supplement for primary offering
10 May 23
FWP
Free writing prospectus
8 May 23
424B5
Prospectus supplement for primary offering
8 May 23
10-Q
2023 Q1
Quarterly report
5 May 23
8-K
Merck Announces First-Quarter 2023 Financial Results
27 Apr 23
PX14A6G
Letter to shareholders
21 Apr 23
Transcripts
MRK
Earnings call transcript
2023 Q1
27 Apr 23
MRK
Earnings call transcript
2022 Q4
2 Feb 23
MRK
Earnings call transcript
2022 Q3
27 Oct 22
MRK
Earnings call transcript
2022 Q2
28 Jul 22
MRK
Earnings call transcript
2022 Q1
28 Apr 22
MRK
Earnings call transcript
2021 Q4
3 Feb 22
MRK
Earnings call transcript
2021 Q3
28 Oct 21
MRK
Earnings call transcript
2021 Q2
29 Jul 21
MRK
Earnings call transcript
2021 Q1
29 Apr 21
MRK
Earnings call transcript
2020 Q4
4 Feb 21
Latest ownership filings
Financial summary
| Quarter (USD) | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 9.79 bn | 9.79 bn | 9.79 bn | 9.79 bn | 9.79 bn | 9.79 bn |
| Cash burn (monthly) | 995.67 mm | (no burn) | (no burn) | (no burn) | (no burn) | (no burn) |
| Cash used (since last report) | 2.18 bn | n/a | n/a | n/a | n/a | n/a |
| Cash remaining | 7.60 bn | n/a | n/a | n/a | n/a | n/a |
| Runway (months of cash) | 7.6 | n/a | n/a | n/a | n/a | n/a |
Institutional ownership, Q1 2023
76.0% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 2966 |
| Opened positions | 151 |
| Closed positions | 236 |
| Increased positions | 1126 |
| Reduced positions | 1341 |
| 13F shares | Current |
|---|---|
| Total value | 198.25 tn |
| Total shares | 1.93 bn |
| Total puts | 10.77 mm |
| Total calls | 13.21 mm |
| Total put/call ratio | 0.8 |
| Largest owners | Shares | Value |
|---|---|---|
| Vanguard | 243.94 mm | $25.95 tn |
| BLK Blackrock | 209.10 mm | $22.25 tn |
| STT State Street | 116.39 mm | $12.47 tn |
| Wellington Management | 68.56 mm | $7.29 tn |
| Ofi Invest Asset Management | 57.94 mm | $544.63 mm |
| Geode Capital Management | 51.22 mm | $5.44 tn |
| BAC Bank Of America | 40.00 mm | $4.26 tn |
| MS Morgan Stanley | 39.04 mm | $4.15 tn |
| FMR | 35.73 mm | $3.80 tn |
| Charles Schwab Investment Management | 30.67 mm | $3.26 tn |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 26 May 23 | Baker Douglas M JR | Phantom Stock Common Stock | Grant | Acquire A | No | No | 111.07 | 1,980.733 | 220.00 k | 4,412.156 |
| 26 May 23 | Coe Mary Ellen | Phantom Stock Common Stock | Grant | Acquire A | No | No | 111.07 | 1,980.733 | 220.00 k | 19,591.346 |
| 26 May 23 | Craig Pamela J. | Phantom Stock Common Stock | Grant | Acquire A | No | No | 111.07 | 1,980.733 | 220.00 k | 25,797.504 |
| 26 May 23 | Glocer Thomas H | Phantom Stock Common Stock | Grant | Acquire A | No | No | 111.07 | 1,980.733 | 220.00 k | 89,950.145 |
| 26 May 23 | Stephen Mayo | Phantom Stock Common Stock | Grant | Acquire A | No | No | 111.07 | 1,980.733 | 220.00 k | 7,430.36 |
News
Moderna and Merck Report Significant Success in Investigational Skin Cancer Therapy, Cuts Risk Of Distant Metastasis Or Death By 65%
5 Jun 23
Medtronic, Merck, Williams Companies And More: CNBC's 'Final Trades'
1 Jun 23
AstraZeneca Announced Lynparza Plus Abiraterone Approved In The US For The Treatment Of BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
1 Jun 23
Analyst Ratings for Merck & Co
30 May 23
Nvidia Becomes Ninth Company To Hit $1-Trillion Market Cap — Which Stock Could Be Next To Join Elusive Club?
30 May 23
Press releases
Moderna and Merck Announce mRNA-4157 (V940) in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following Complete Resection Versus KEYTRUDA
5 Jun 23
Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as a Single Agent After Surgery Reduced the Risk of Event-Free Survival Events by 42% Versus Pre-Operative Chemotherapy in Resectable Stage II, IIIA or IIIB NSCLC
3 Jun 23
KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone as First-Line Treatment for Unresectable Advanced Pleural Mesothelioma
3 Jun 23
FDA Approves LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone for Treatment of Adult Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC)
1 Jun 23
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma
25 May 23